I am a radiation oncologist specializing in cancers of the gastrointestinal tract. My goal is to introduce the most cutting-edge technology in radiation oncology to the treatment of GI malignancies, including intensity-modulated radiation therapy, image-guided radiation therapy, and stereotactic body radiotherapy, with the intent of reducing toxicity and improving our results from radiation therapy. In addition to my interest in technical advances in radiation oncology, I am also involved in the development of therapeutic protocols combining radiation, chemotherapy, and targeted agents for gastrointestinal cancers. I am also interested in quality of life and late effects after radiotherapy.
- Clinical Expertise: Anal Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Rectal Cancer, Pancreas Cancer; Hepatobiliary Cancers
- Languages Spoken: English
- Education: MD, Stanford University School of Medicine; MS in Epidemiology, Harvard School of Public Health
- Residencies: Stanford University Medical Center; Memorial Sloan Kettering Cancer Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Radiation Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Karyn A. Goodman
- A Phase I Study of High-Dose-Rate Brachytherapy plus Chemotherapy in Patients with Recurrent Rectal or Anal Cancer
- A Phase III Study of Sorafenib Alone versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Patients with Liver Cancer
- A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Pancreatic Cancer
Clinical Trials Co-Investigated by Karyn A. Goodman
- A Phase II Study of Chemotherapy and Chemoradiation Followed by Surgery or Non-Operative Management in Patients with Stage II or III Rectal Cancer
- A Phase II Study of Pembrolizumab plus Radiation Therapy or Ablation to Treat Metastatic Colorectal Cancer
- Chemotherapy Alone or with Radiation Therapy for Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery